Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mesothelioma and SCLC

4986 - Top-line data from the randomized phase 2 IMPULSE study in small-cell lung cancer (SCLC): Immunotherapeutic maintenance treatment with lefitolimod


10 Sep 2017


Mesothelioma and SCLC


Immunotherapy;  Small Cell Lung Cancer


Michael Thomas


Annals of Oncology (2017) 28 (suppl_5): v539-v542. 10.1093/annonc/mdx386


M. Thomas1, S. Ponce-Aix2, A. Navarro Mendivil3, J. Riera Knorrenschild4, M. Schmidt5, M. Krikow6, E. Wiegert6, M. Domine Gomez7, J. Kollmeier8, P. Sadjadian9, K.P. Fröhling10, R.M. Huber11, M. Wolf12

Author affiliations

  • 1 Oncology, Thoraxklinik at the Heidelberg University Medical Center and Translational Lung Research Center Heidelberg (TLRC-H), The German Center for Lung Research (DZL), 69126 - Heidelberg/DE
  • 2 Medical Oncology, Hospital 12 de Octubre, Madrid/ES
  • 3 Vall D' Hebron Institute Of Research (vhir), Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 4 Hämatologie, Onkologie Und Immunologie, Klinikum der Philipps Universität Marburg, Marburg/DE
  • 5 Translational Research, Mologen AG, 14195 - Berlin/DE
  • 6 Clinical Department, Mologen AG, 14195 - Berlin/DE
  • 7 Medical Oncology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 8 Klinik Für Pneumologie, HELIOS Klinikum Emil von Behring GmbH, Berlin/DE
  • 9 Abteilung Pneumologie, Johannes Weseling Klinikum, 32429 - Minden/DE
  • 10 Pneumologie, Kath. Klinikum Koblenz-Montabaur, Koblenz/DE
  • 11 Division Of Respiratory Medicine And Thoracic Oncology, University Hospital of Munich, Munich/DE
  • 12 Medizinische Klinik Iv, Klinikum Kassel, 34125 - Kassel/DE


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 4986


The immune surveillance reactivator lefitolimod (MGN1703), a DNA-based TLR9 agonist, is currently in a comprehensive clinical development program including a phase 3 trial in mCRC. The phase 2 IMPULSE study was designed to evaluate the efficacy and safety of lefitolimod in small-cell lung cancer (SCLC).


IMPULSE is a randomized, international, multicenter, open-label trial to assess the effect of lefitolimod-mediated immune surveillance reactivation on overall survival (OS) in extensive-disease SCLC. 102 patients with objective tumor response following 4 cycles of platinum-based first-line induction therapy were randomized 3:2 to receive either lefitolimod maintenance therapy or local standard of care (control). Upon relapse, patients have received appropriate second-line therapy.


Out of 102 patients, 61 were randomized to the lefitolimod, 41 to the control arm. Distribution of patients to the two arms was balanced regarding patient demographics. Even though in this highly challenging indication the primary endpoint OS of the overall study population was not met, IMPULSE showed positive results in two pre-defined and clinically relevant subgroups: An OS benefit was shown in comparison with the control arm in patients with a low count of activated CD86+ B cells (HR 0.59, 95%CI 0.29-1.21, n = 38 of 88) as well as in patients with reported chronic obstructive pulmonary disease (COPD), (HR 0.54, 95%CI 0.21-1.38, n = 25 of 102). Immunologic parameters confirmed lefitolimod’s mode-of-action with a clear activation of CD169+ monocytes and production of IP-10 in response to lefitolimod treatment. Lefitolimod showed a favorable safety profile in this vulnerable population.


The IMPULSE study showed (1) the expected pharmacodynamic response to lefitolimod, (2) positive efficacy signals in two pre-defined and clinically relevant subgroups regarding OS and (3) a favorable safety profile. This data provides significant guidance for defining patient populations most likely to benefit from treatment with lefitolimod.

Clinical trial identification


Legal entity responsible for the study

Mologen AG


Mologen AG


M. Schmidt, M. Krikow, E. Wiegert: Employee. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.